| Literature DB >> 33584256 |
Shuang Hu1,2, Pan-Pan Lian3, Ying Hu1,2, Xing-Yu Zhu4, Shao-Wei Jiang5, Qiang Ma6, Liang-Yun Li1,2, Jun-Fa Yang1,2, Li Yang1,2, Hai-Yue Guo1,2, Hong Zhou1,2, Chen-Chen Yang1,2, Xiao-Ming Meng1,2, Jun Li1,2, Hai-Wen Li7, Tao Xu1,2, Huan Zhou4.
Abstract
It is known that liver diseases have several characteristics of massive lipid accumulation and lipid metabolic disorder, and are divided into liver inflammation, liver fibrosis, liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in patients. Interleukin (IL)-35, a new-discovered cytokine, can protect the liver from the environmental attack by increasing the ratio of Tregs (T regulatory cells) which can increase the anti-inflammatory cytokines and inhibit the proliferation of immune cellular. Interestingly, two opposite mechanisms (pro-inflammatory and anti-inflammatory) have connection with the ultimate formation of liver diseases, which suggest that IL-35 may play crucial function in the process of liver diseases through immunosuppressive regulation. Besides, some obvious advantages also imply that IL-35 can be considered as a new therapeutic target to control the progression of liver diseases, while its mechanism of function still needs further research.Entities:
Keywords: Interleukin-35; cellular proliferation; hepatocellular carcinoma; lipid accumulation; liver diseases
Year: 2021 PMID: 33584256 PMCID: PMC7873894 DOI: 10.3389/fphar.2020.569575
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810